Analysis of DNA Methylation in Stroke

DNA methylation is the most fully characterized epigenetic mechanism, playing a key role in regulating global and specific gene expression profiles and promoting important cellular processes. Aberrant DNA methylation is associated with a variety of human diseases, such as ischemic stroke. The role of DNA methylation in cerebral ischemia is multifaceted, with genome-wide and gene-specific effects that influence vulnerability to CNS injury. Molecular studies using animal models of stroke have shown that increased levels of DNA methylation in ischemic brain tissue lead to increased brain damage. Investigating the role of DNA methylation in neuroprotection and functional recovery after stroke could contribute to the development and application of novel therapeutic strategies for stroke.

Fig. 1. Investigating the role of DNA methylation could contribute to the development and application of new therapeutic strategies for stroke.Fig. 1. Analysis of DNA methylome in post-TE stroke BBB recovery. (Phillips et al., 2023)

Our Services

Ace Therapeutics' multidisciplinary team employs advanced technologies to help clients analyze the mechanisms of neuronal death and neural repair through DNA methylation regulation after stroke.

Identification and Validation of DNA Methylation-Related Targets in Stroke

We provide RNA sequencing and simplified representative bisulfite sequencing (RRBS) for the discovery of DNA methylation-related targets in stroke. DNA methylation-related targets that have been identified include:

BDNF ND2, ND3, ND4L, ND5, ND6, and COX3 Timp-2 Arid5a, Nptx2, Stc2

Analysis of DNA Methylation in Experimental Models of Stroke

We help clients analyze the role of specific gene regulation mediated by DNA methylation in the pathophysiology of stroke in animal models of stroke and in vitro experiments.

  • We use high-throughput sequencing technologies (e.g., Illumina microarrays or whole-genome sulfite sequencing) to analyze the DNA methylation status of the entire genome to help our clients discover genome-wide differentially methylated regions associated with stroke.
  • We can test the methylation status of specific genes known to be associated with stroke.
  • We analyze DNA methylation levels of individual genes (e.g., BDNF, NOS3, STAT3) and their association with stroke.
  • We help clients screen for differentially methylated genes or regions and evaluate them as potential biomarkers for stroke diagnosis or prognosis prediction.

Ace Therapeutics is committed to providing experimental data on the regulation of DNA methylation in post-stroke neuroprotection and neuronal repair mechanisms. Through advanced methodologies and partnerships, we aim to accelerate the R&D process for our clients to develop new therapeutic strategies for stroke. If you are interested in our services, please do not hesitate to contact us!

  1. Phillips, C. M., et al. (2023). Epigenetics and stroke: role of DNA methylation and effect of aging on blood–brain barrier recovery. Fluids and Barriers of the CNS, 20(1), 14.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Inquiry Basket